scholarly journals Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial

Diabetes Care ◽  
2017 ◽  
Vol 41 (2) ◽  
pp. 333-340 ◽  
Author(s):  
Julio Rosenstock ◽  
John B. Buse ◽  
Rehan Azeem ◽  
Prakash Prabhakar ◽  
Lise Kjems ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Efficacy And Safety ◽  
Oral Antidiabetes Drugs ◽  
Novel Drug

78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 78-LB
Author(s):  
BERNHARD LUDVIK ◽  
FRANCESCO GIORGINO ◽  
ESTEBAN JODAR ◽  
JUAN PABLO FRIAS ◽  
LAURA FERNANDEZ LANDO ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Insulin Degludec ◽  
Efficacy And Safety

100-OR: ADA Presidents’ Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1)

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 100-OR
Author(s):  
JULIO ROSENSTOCK ◽  
CAROL H. WYSHAM ◽  
JUAN P. FRIAS ◽  
SHIZUKA KANEKO ◽  
CLARE LEE ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Efficacy And Safety ◽  
Select Abstract

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

2013 ◽  
Vol 145 (3) ◽  
pp. 574-582.e1 ◽  
Author(s):  
Sunder Mudaliar ◽  
Robert R. Henry ◽  
Arun J. Sanyal ◽  
Linda Morrow ◽  
Hanns–Ulrich Marschall ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Receptor Agonist ◽  
Farnesoid X Receptor ◽  
Efficacy And Safety ◽  
Obeticholic Acid ◽  
Nonalcoholic Fatty Liver

scholarly journals Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials

2021 ◽  
Vol 14 (10) ◽  
pp. 991
Author(s):  
Akshaya Srikanth Bhagavathula ◽  
Kota Vidyasagar ◽  
Wubshet Tesfaye
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Body Weight ◽  
Receptor Agonist ◽  
Meta Analysis ◽  
Serum Glucose ◽  
Efficacy And Safety ◽  
Fasting Serum

Tirzepatide is a novel once-a-week dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, currently under trial to assess glycemic efficacy and safety in people with type 2 diabetes. A systematic review and meta-analysis were conducted to investigate the efficacy of tirzepatide on glycated hemoglobin (HbA1c, %), fasting serum glucose (mg/dL), and body weight (kg) in patients with uncontrolled type 2 diabetes (HbA1c > 7.0%). Mean changes for efficacy and proportions (safety) with corresponding 95% confidence intervals (CIs) were used to provide pooled estimates. A total of four randomized controlled trials, comprising 2783 patients of whom 69.4% (n = 1934) were treated with 5 mg (n = 646), 10 mg (n = 641), or 15 mg (n = 647) of tirzepatide, were compared to the placebo (n = 192) or the selective GLP-1 receptor agonist (n = 523). The pooled analysis showed that tirzepatide treatment resulted in a greater lowering of the HbA1c (−1.94%, 95% CI: −2.02 to −1.87), fasting serum glucose (−54.72 mg/dL, 95% CI: −62.05 to −47.39), and body weight (−8.47, 95% CI: −9.66 to −7.27). We also found that improvement in the HbA1c levels was still maintained at weeks 26 and 40 from the long-term trials. As for safety, only 3% experienced hypoglycemia, and 4% (95% CI: 2 to 6) experienced serious adverse events, while the discontinuation of therapy percentage was 7% (95% CI: 5 to 8). Tirzepatide significantly improved glycemic control and body weight and had an acceptable safety profile, indicating that it is an effective therapeutic option for glucose-lowering in patients with type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document